Navigation Links
Nanotech researchers' 2-step method shows promise in fighting pancreatic cancer
Date:11/15/2013

Researchers at UCLA's Jonsson Comprehensive Cancer Center have developed a new technique for fighting deadly and hard-to-treat pancreatic cancer that uses two different types of nanoparticles, the first type clearing a path into tumor cells for the second, which delivers chemotherapy drugs.

The research team, led by Dr. Andre Nel, a UCLA professor of nanomedicine and a member of the California NanoSystems Institute at UCLA, and Dr. Huan Meng, a UCLA adjunct assistant professor of nanomedicine, has shown that this new drug-delivery technique is effective in treating pancreatic cancer in a mouse model.

The results of the study are published online in the journal ACS Nano and will be featured in the November 2013 print issue.

Pancreatic ductal adenocarcinoma, or pancreatic cancer, is a deadly disease that is nearly impossible to detect until it is in the advanced stage. Treatment options are limited and have low success rates. The need for innovative and improved treatment of pancreatic cancer cannot be overstated, the researchers said, as a pancreatic cancer diagnosis has often been synonymous with a death sentence.

Pancreatic ductal adenocarcinoma tumors are made up of cancer cells that are surrounded by other structural elements called stroma. The stroma can be made of many substances, including connective tissue and pericyte cells, which block standard chemotherapy drugs in tumor blood vessels from efficiently reaching the cancer cells, reducing the effectiveness of treatment.

The dual-wave nanotherapy method employed by Nel and Meng uses two different kinds of nanoparticles injected intravenously in a rapid succession. The first wave of nanoparticles carries a substance that removes the pericytes' vascular gates, opening up access to the pancreatic cancer cells; the second wave carries the chemotherapy drug that kills the cancer cells.

Nel and Meng, along with colleagues Dr. Jeffrey Zink, a UCLA professor of chemistry and biochemistry, and Dr. Jeffrey Brinker, a University of New Mexico professor of chemical and nuclear engineering, sought to place chemotherapy drugs into nanoparticles that could more directly target pancreatic cancer cells, but they first needed to find a way to get those nanoparticles through the sites of vascular obstruction caused by pericytes, which restrict access to the cancer cells.

Through experimentation, they discovered they could interfere with a cellular signaling pathway the communication mechanism between cells that governs the pericytes' attraction to the tumor blood vessels. By creating nanoparticles that effectively bind a high load of the signaling pathway inhibitor, the researchers were able to develop a first wave of nanoparticles that would separate the pericytes from the endothelial cells on the blood vessel. This would open the vascular gate for the next wave of nanoparticles, which carry the chemotherapeutic agent to the cancer cells inside the tumor.

To test this nanotherapy, the researchers used immuno-compromised mice in which they grew human pancreatic tumors called xenografts under the skin. With the two-wave method, the xenograft tumors had a significantly higher rate of shrinkage than tumors exposed only to chemotherapy given as a free drug or carried in nanoparticles without first-wave treatment.

"This two-wave nanotherapy is an existing example of how we seek to improve the delivery of chemotherapy drugs to their intended targets using nanotechnology to provide an engineered approach," said Nel, chief of UCLA's division of nanomedicine. "It shows how the physical and chemical principles of nanotechnology can be integrated with the biological sciences to help cancer patients by increasing the effectiveness of chemotherapy while also reducing side effects and toxicity. This two-wave treatment approach can also address biological impediments in nanotherapies for other types of cancer."


'/>"/>

Contact: Shaun Mason
smason@mednet.ucla.edu
310-206-2805
University of California - Los Angeles
Source:Eurekalert

Related medicine news :

1. Giving transplanted cells a nanotech checkup
2. Furnace Accelerator Startup SiO2 Nanotech Develops Anti-Fogging Technology for Variety of Applications
3. Outlook with Ben Kingsley Exploring Role of Nanotechnology in Medicine for Upcoming Report
4. Nanotech system, cellular heating may improve treatment of ovarian cancer
5. CWRU researchers aim nanotechnology at micrometastases
6. NIH awards $20 million over 5 years to train next generation of global health researchers
7. Researchers develop a new cell and animal model of inflammatory breast cancer
8. Researchers uncover a viable way for colorectal cancer patients to overcome drug resistance
9. Researchers Find Gene Mutations That May Be a Key to Autism
10. Researchers find evidence of banned antibiotics in poultry products
11. NJ stroke researchers report advances in spatial neglect research at AAN Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... ... 2017 partnership with The Jensie Gran Fondo of Marin. For the second year ... with Thinksport’s broad-spectrum, mineral-based sunscreen. , “We are thrilled to provide our safe, ...
(Date:2/23/2017)... ... 23, 2017 , ... The Lymphoma Research Foundation (LRF) – ... serving the lymphoma community through a comprehensive series of education programs, outreach initiatives ... Miami Beach to host its Swirl: Miami Wine Tasting Event on March 28, ...
(Date:2/23/2017)... ... February 23, 2017 , ... Los Angeles-based weight loss surgeon Michael ... “Mama June: From Not to Hot,” which will begin airing on February 24, 2017. ... to millions from the 2012 reality television series, “Here Comes Honey Boo Boo.” The ...
(Date:2/23/2017)... ... February 23, 2017 , ... EBSCO ... the National Institute for Health and Care Excellence (NICE) framework. The ... National Health Service (NHS) to search, order and purchase medical and healthcare-related content ...
(Date:2/23/2017)... ... February 23, 2017 , ... Pink ... publication where generations converge and explore the world from different perspectives. By providing ... enables readers to gain understanding, increase empathy, and find greater happiness. , ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... , Feb. 23, 2017 Non-alcoholic ... on the various drugs being developed for ... all the drugs that are in various ... The pipeline focuses on novel pharmacologic drugs ... stem cell therapies, recombinant proteins and RNA-based ...
(Date:2/24/2017)... -- Xynomic Pharmaceuticals, Inc., an oncology drug research and ... exclusive worldwide rights to develop, manufacture and commercialize ... hematological and solid tumors. To date ... clinical trials of Abexinostat in US, EU and ... completed, demonstrating that Abexinostat is clinically active in ...
(Date:2/23/2017)... Research and Markets has announced the addition of the ... report to their offering. ... The latest research Autism Spectrum Disorder Drugs Price Analysis ... the global Autism Spectrum Disorder market. The research answers the ... drugs marketed for Autism Spectrum Disorder and their clinical attributes? How ...
Breaking Medicine Technology: